Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eladocagene Exuparvovec→

Eladocagene Exuparvovec Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2098615-91-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Adeno-associated virus serotype 2 (AAV2) gene therapy delivering the DDC gene
Mechanism of action
A recombinant AAV2 vector delivers a functional copy of the DDC gene encoding aromatic L-amino acid decarboxylase (AADC) to cells in the putamen. The transduced cells produce AADC, supporting conversion of L-DOPA to dopamine in patients with AADC deficiency.
Indications / reported uses
  • Treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency under the applicable product authorisation; age criteria and specialist administration requirements are label-specific

Sources: US DailyMed — KEBILIDI (eladocagene exuparvovec) · US FDA product information — KEBILIDI · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eladocagene Exuparvovec Environmental Risk Assessment (ERA) (the Eladocagene Exuparvovec ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.